GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5466 Neuromedin S (rat)Summary: endogenous neuromedin U receptor agonist -
B5472 Boc-MLFSummary: formyl peptide receptor 1 (FPR1) antagonist -
B5476 Hemopressin (human, mouse)Summary: CB1 receptor inverse agonist; endogenous peptide substrate for endopeptidase 24.15 (ep24.15), neurolysin (ep24.16) and ACE -
B5480 MCH (human, mouse, rat)Summary: melanin-concentration hormone (MCH) receptors agonist -
B5489 Kisspeptin 234Summary: A kisspeptin receptor antagonist -
B5497 Orphanin FQ (1-11)Summary: ORL1/KOR-3 receptor agonist -
B5498 RWJ 52353Summary: α2D adrenergic receptor agonist -
B5506 MEN 11270Summary: B2 bradykinin receptor antagonist -
B5518 MRE 3008F20Summary: adenosine A3 receptor antagonist -
B5546 MRS 2957 triethylammonium saltSummary: P2Y6 agonist

